NO331820B1 - Syntetiske humane peptider og peptidpolymerer, anvendelse av disse for fremstilling av farmasoytiske sammensetninger, farmasoytiske sammensetninger for behandling av systemisk lupus erythematosus samt fremgangsmate for a vurdere effekten til et legemiddel inneholdende peptid eller peptidpolymer. - Google Patents

Syntetiske humane peptider og peptidpolymerer, anvendelse av disse for fremstilling av farmasoytiske sammensetninger, farmasoytiske sammensetninger for behandling av systemisk lupus erythematosus samt fremgangsmate for a vurdere effekten til et legemiddel inneholdende peptid eller peptidpolymer. Download PDF

Info

Publication number
NO331820B1
NO331820B1 NO20033718A NO20033718A NO331820B1 NO 331820 B1 NO331820 B1 NO 331820B1 NO 20033718 A NO20033718 A NO 20033718A NO 20033718 A NO20033718 A NO 20033718A NO 331820 B1 NO331820 B1 NO 331820B1
Authority
NO
Norway
Prior art keywords
peptide
mmp
seq
sle
mice
Prior art date
Application number
NO20033718A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033718D0 (no
NO20033718L (no
Inventor
Edna Mozes
Original Assignee
Veda Res And Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veda Res And Dev Co Ltd filed Critical Veda Res And Dev Co Ltd
Publication of NO20033718D0 publication Critical patent/NO20033718D0/no
Publication of NO20033718L publication Critical patent/NO20033718L/no
Publication of NO331820B1 publication Critical patent/NO331820B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20033718A 2001-02-26 2003-08-21 Syntetiske humane peptider og peptidpolymerer, anvendelse av disse for fremstilling av farmasoytiske sammensetninger, farmasoytiske sammensetninger for behandling av systemisk lupus erythematosus samt fremgangsmate for a vurdere effekten til et legemiddel inneholdende peptid eller peptidpolymer. NO331820B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14164701A IL141647A0 (en) 2001-02-26 2001-02-26 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
PCT/IL2002/000148 WO2002067848A2 (en) 2001-02-26 2002-02-26 PEPTIDES FROM THE 16/6id ANTIBODY FOR TREATING SLE

Publications (3)

Publication Number Publication Date
NO20033718D0 NO20033718D0 (no) 2003-08-21
NO20033718L NO20033718L (no) 2003-10-09
NO331820B1 true NO331820B1 (no) 2012-04-10

Family

ID=11075174

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033718A NO331820B1 (no) 2001-02-26 2003-08-21 Syntetiske humane peptider og peptidpolymerer, anvendelse av disse for fremstilling av farmasoytiske sammensetninger, farmasoytiske sammensetninger for behandling av systemisk lupus erythematosus samt fremgangsmate for a vurdere effekten til et legemiddel inneholdende peptid eller peptidpolymer.

Country Status (28)

Country Link
US (2) US20040127408A1 (pl)
EP (1) EP1370575B1 (pl)
JP (1) JP4316886B2 (pl)
KR (1) KR100860735B1 (pl)
CN (1) CN1309733C (pl)
AT (1) ATE346094T1 (pl)
AU (1) AU2002233618B2 (pl)
BR (1) BR0207586A (pl)
CA (1) CA2439051C (pl)
CR (1) CR7058A (pl)
CU (1) CU23276B7 (pl)
DE (1) DE60216243T2 (pl)
DK (1) DK1370575T3 (pl)
EA (1) EA009465B1 (pl)
EC (1) ECSP034743A (pl)
ES (1) ES2275832T3 (pl)
HR (1) HRP20030667A2 (pl)
HU (1) HU230372B1 (pl)
IL (3) IL141647A0 (pl)
IS (1) IS6908A (pl)
MX (1) MXPA03007622A (pl)
NO (1) NO331820B1 (pl)
NZ (1) NZ527499A (pl)
PL (1) PL373520A1 (pl)
PT (1) PT1370575E (pl)
SI (1) SI1370575T1 (pl)
WO (1) WO2002067848A2 (pl)
ZA (1) ZA200305874B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292846A1 (en) * 2000-09-20 2002-04-29 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
KR20050100616A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신성 홍반성 낭창의 치료를 위한 펩티드의 비경구 제제
EP1594434B1 (en) * 2003-01-14 2016-09-07 Yeda Research and Development Co. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8313950B2 (en) * 2007-05-21 2012-11-20 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
EP3052526A4 (en) 2013-10-03 2017-04-19 Oregon Health & Science University Recombinant polypeptides comprising mhc class ii 1 domains
WO2018127914A1 (en) 2017-01-05 2018-07-12 Yeda Research And Development Co. Ltd. Peptides for treating sjogren's syndrome
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用
WO2025008818A1 (en) * 2023-07-03 2025-01-09 Dan Goldstaub Compositions and methods for treatment of systemic lupus erythematosus
WO2025027013A1 (en) * 2023-08-01 2025-02-06 Diamante Srl Composition and methods for treating system lupus erythematosus

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127408A (en) * 1872-06-04 Improvement in tooth-powders or dentifrices
US8634A (en) * 1852-01-06 Wool-pickina machine
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
GB2290293A (en) * 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
US6613536B1 (en) * 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US20020054872A1 (en) * 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
IL120503A0 (en) * 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
ES2302363T3 (es) * 1997-12-18 2008-07-01 Boehringer Ingelheim Pharmaceuticals Inc. Piridonas como inhibidores del dominia sh2 del grupo src.
KR100261262B1 (ko) * 1998-02-03 2000-08-01 윤종용 반도체 습식 설비의 구조 및 이의 로트 로딩/언로딩 방법
US6415877B1 (en) * 1998-07-15 2002-07-09 Deep Vision Llc Subsea wellbore drilling system for reducing bottom hole pressure
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
EP1594434B1 (en) * 2003-01-14 2016-09-07 Yeda Research and Development Co. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
KR20050100616A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신성 홍반성 낭창의 치료를 위한 펩티드의 비경구 제제

Also Published As

Publication number Publication date
NO20033718D0 (no) 2003-08-21
PL373520A1 (pl) 2005-09-05
CA2439051A1 (en) 2002-09-06
WO2002067848A3 (en) 2002-12-12
CN1309733C (zh) 2007-04-11
AU2002233618B2 (en) 2006-12-21
KR20030092004A (ko) 2003-12-03
US7858738B2 (en) 2010-12-28
JP4316886B2 (ja) 2009-08-19
PT1370575E (pt) 2007-01-31
EA009465B1 (ru) 2007-12-28
CN1503806A (zh) 2004-06-09
CA2439051C (en) 2010-02-02
CU23276B7 (es) 2008-04-09
DK1370575T3 (da) 2007-01-29
ECSP034743A (es) 2004-01-28
IS6908A (is) 2003-08-11
US20040127408A1 (en) 2004-07-01
DE60216243D1 (de) 2007-01-04
HU230372B1 (hu) 2016-03-29
JP2005505493A (ja) 2005-02-24
EP1370575A2 (en) 2003-12-17
US20080119390A1 (en) 2008-05-22
DE60216243T2 (de) 2007-10-31
IL157550A (en) 2010-05-31
SI1370575T1 (sl) 2007-04-30
HRP20030667A2 (en) 2005-06-30
EP1370575B1 (en) 2006-11-22
ATE346094T1 (de) 2006-12-15
WO2002067848A2 (en) 2002-09-06
IL157550A0 (en) 2004-03-28
NO20033718L (no) 2003-10-09
EP1370575A4 (en) 2004-09-29
ES2275832T3 (es) 2007-06-16
KR100860735B1 (ko) 2008-09-29
EA200300939A1 (ru) 2004-12-30
NZ527499A (en) 2005-12-23
BR0207586A (pt) 2006-11-07
IL141647A0 (en) 2002-03-10
HUP0600778A2 (en) 2007-01-29
MXPA03007622A (es) 2004-09-14
HK1059790A1 (en) 2004-07-16
ZA200305874B (en) 2005-08-31
CR7058A (es) 2004-11-01
HUP0600778A3 (en) 2012-09-28

Similar Documents

Publication Publication Date Title
US7858738B2 (en) Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US20260035483A1 (en) Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
US10745274B1 (en) Nucleic acids encoding antibodies specifically binding to MASP-3
AU2002233618A1 (en) Peptides from the 16/6Id antibody for treating SLE
HK1059790B (en) Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
OA19469A (en) Compositions and methods of inhibiting MASP-3 for the treatment of various deseases and disorders.

Legal Events

Date Code Title Description
MK1K Patent expired